Brazil · Delayed Price · Currency is BRL Empreendimentos Pague Menos Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 6.9% YoY, adjusted EBITDA rose 16.9%, and Q3 EBITDA margin was 6.3%. LTM cash generation reached BRL 690 million as leverage fell to 1.8x, while digital and continuous-care initiatives advanced.
-
Record Q2 profitability and cash generation were driven by strong same-store sales, disciplined expense control, and market share gains, despite digital channel issues impacting GLP-1 sales. Continued deleveraging, robust investments in technology, and assertive store openings support a positive outlook.
-
Q1 2026 saw 14.4% revenue growth, 36% EBITDA growth, and net income quadrupling year-over-year, with strong market share gains in the North and Northeast and a focus on continuous care customers. Margin expansion, disciplined capital allocation, and digital growth underpin a positive outlook.
Fiscal Year 2025
-
Achieved record revenue and EBITDA growth in 2025, driven by strong same-store sales, digital expansion, and operational efficiency. Market share and profitability improved, with disciplined capital allocation and a focus on scaling logistics and generics in 2026.
-
Revenue grew 18% year-over-year, with same-store sales up 17.6% and EBITDA rising 36.4%. Prescription and generic drugs drove growth, while net income increased 50%. Market share, customer base, and store productivity all improved, with further gains expected.
-
Record revenue and profit growth driven by strong prescription drug sales, digital expansion, and operational excellence. Market share and productivity gains outpaced industry peers, with digital now 18.7% of sales and ROIC at 22.9%.
-
Q1 2025 saw 17% revenue growth, a 55% EBITDA increase, and a return to net profit, driven by strong same-store and digital sales, improved stock management, and disciplined execution. Leverage and expenses declined, while market share and ROI rose, despite margin pressures from sales mix and digital expansion.
Fiscal Year 2024
-
Record 2024 results featured double-digit revenue and profit growth, strong operational improvements, and successful Extrafarma integration. Expansion and deleveraging will continue in 2025, with multiple growth levers and a positive sales outlook despite industry headwinds.
-
Q3 2024 saw record revenue, EBITDA, and net income, driven by strong same-store sales, margin gains, and successful integration of Extrafarma. Leverage and financial expenses declined, with robust free cash flow and continued market share gains.
-
Delivered 12% sales growth, 11.4% same-store sales growth, and reversed prior-year losses with BRL 44.2 million net income. Achieved record cash flow, reduced leverage, and captured BRL 203 million in annualized synergies from Extrafarma integration.